A reality no one was seeing
A forty-year-old woman carries forty-year-old eggs. Her partner produces sperm that also bears the marks of his own ageing. The resulting zygote therefore begins its life with damaged biological material, marked by decades of accumulated errors, partially repaired damage, a worn epigenome.
And yet, two weeks after fertilisation, this zygote has become an embryo whose cells are as young as those of a freshly laid egg. Everything has been erased, reset to zero. A child is born biologically new, whatever the wear of its progenitors.
For decades, this fact was taught in biology textbooks as one curiosity among others. It was observed, noted, and set aside. It turns out the question that would change everything had not yet been asked: by what mechanism? How does a damaged cell manage to rewrite itself completely while keeping its identity?
This question is finding its first serious answers. It is probably one of the greatest conceptual breakthroughs in biology since the double helix of Watson and Crick in 1953.
An experiment in Kyoto, in 2006
Shinya Yamanaka is a discreet Japanese biologist, a professor at the University of Kyoto. A specialist in embryonic stem cells, he has for years been interested in a question that seemed absurd to the biological dogma of the time: can a differentiated cell be pushed back towards a younger state?
In 2006, his team publishes the experiment that will earn him the Nobel Prize six years later. Yamanaka takes a skin cell from an adult mouse. A differentiated, specialised cell that long ago gave up any identity other than its own. He introduces into its nucleus four precise proteins, which will from now on be called the Yamanaka factors. The skin cell becomes an embryonic stem cell again, able to turn into any tissue of the body.
The scientific community is stunned. Not because the manipulation is technically spectacular, but because it demonstrates something all the textbooks presented as impossible: cell differentiation is not a one-way street. It is reversible. The biological time of a cell can be rewound.
And then, for more than ten years, the research advances quietly, far from magazine covers. The reason is simple: Yamanaka has shown that a cell can be rejuvenated, but the cost is enormous. The skin cell brought back to the stem state loses its identity as a skin cell. It can now become anything, including something uncontrollable. In the human body, that something is called a tumour.
To treat patients, something else will have to be found.
The idea that unlocked everything
In 2016, a Spanish biologist working at the Salk Institute in California, Juan Carlos Izpisua Belmonte, had an idea of almost insolent simplicity. If full reprogramming erases cell identity, then why not reprogram partially? Why not apply the Yamanaka factors just long enough to erase the marks of ageing, but not long enough to erase what the cell has become?
The computing analogy imposes itself here and it is not just a metaphor. DNA is a cell's hardware. The epigenome, that is the set of chemical marks placed on the DNA, is its software. It is what tells each cell which genes to activate, which to repress, how to behave. As we age, this software degrades. The instructions become contradictory, the cells lock into dysfunctional intermediate states and lose their ability to respond correctly to attacks.
Yamanaka had discovered how to perform a full reset of the system. Izpisua Belmonte discovers how to apply a targeted patch.
The results published in 2016 exceed what the community hoped for. On mice suffering from a form of accelerated ageing, the transient application of the Yamanaka factors extends lifespan, restores the function of several organs and attenuates the cellular markers of ageing. On human cells in the laboratory, the results are even more striking: fibroblasts taken from ninety-six-year-old people recover a gene expression profile characteristic of sixty-year-old cells. Their fibroblast identity has remained intact. Their epigenome has rejuvenated by thirty years.
Three billion dollars and a team of Nobel laureates
In January 2022, an American company comes into being with means quite unusual for biotech. Altos Labs raises three billion dollars in initial funding. Among its investors, the Russian-Israeli billionaire Yuri Milner and, according to several converging sources, Jeff Bezos.
Where other longevity ventures might look like the scientific tourism of billionaires in search of youth, Altos does something different. The company recruits the world's front rank of ageing biology. Shinya Yamanaka joins as a scientific adviser. Jennifer Doudna, co-inventor with Emmanuelle Charpentier of CRISPR and Nobel laureate in chemistry in 2020, joins the board. Steve Horvath, inventor of the epigenetic clocks that measure the real biological age of a cell independently of its chronological age, takes charge of a laboratory. Izpisua Belmonte himself is recruited as a scientific founder.
Altos Labs is not a start-up. It is, in its stated ambition as in the quality of its recruitment, the greatest concentration of brains ever assembled on the question of cellular rejuvenation. And for three years, the publications have piled up at a pace that surprises even the field's most seasoned observers.
Cardiac muscle cells from ageing mice have been successfully rejuvenated. Rat kidneys have been removed from the body, treated by partial reprogramming outside the organism, then re-transplanted. The animals survived, the kidneys recovered normal function. Altos's scientific founder recently revealed that the same approach is being applied to human organs kept alive on perfusion machines. This means that human kidneys or livers, taken from donors too old to be transplanted as they are, could tomorrow be rejuvenated before grafting.
The first human eye
While Altos advances on organs, another team is tracing a parallel route. David Sinclair, a researcher at Harvard, has been one of the pioneers of ageing biology for twenty years. His company, Life Biosciences, filed at the end of 2025 a submission with the American FDA for a human clinical trial of partial epigenetic reprogramming. Authorisation was granted in January 2026.
The therapy is called ER-100. It aims to treat glaucoma, a disease that gradually degrades the optic nerve and remains one of the leading causes of blindness in the world. The idea is to apply the Yamanaka factors, via localised gene therapy, to the retinal ganglion cells that die during the disease. If these cells can be rejuvenated, their survival could be prolonged and the loss of vision slowed, or even stopped.
For the first time in the history of medicine, a living human cell is treated by partial epigenetic reprogramming within an official clinical protocol. This is no longer science fiction but a regulatory file with patient numbers, monitoring committees and evaluation criteria at six months and one year.
The first patient was enrolled in Boston in March 2026.
What really changed
There is a lazy way to read this research: billionaires want to live forever and pay brilliant scientists to help them. That reading is not false, but it misses the essential.
What happened between 2006 and 2026 is a breakthrough in the conceptual frame around the very nature of ageing. For centuries, ageing was treated as a given. Something medicine could push back at the margins, through antibiotics, surgery, nutrition, but never question in principle. This conviction structured whole swathes of medical research, health economics and the organisation of care systems.
What Yamanaka, Sinclair, Izpisua Belmonte and their teams have demonstrated is that ageing is not a fatality inscribed in the genetic material. It is an epigenetic state. A state that degrades over time and that, at least partially, can be repaired. Ageing thus moves from the status of destiny to that of mechanism. And a mechanism, by definition, is something one can act on.
This change of status resembles other breakthroughs the history of science has given us. When Louis Pasteur demonstrated in 1864 that certain diseases were caused by micro-organisms, he did not only open the way to antibiotics eighty years later. He changed the way humanity thought about disease. Infection moved from destiny to mechanism. When Newton published his Principia in 1687, he did not merely explain the motion of the planets, he turned the fall of an apple and the ballet of the stars into two instances of the same equation.
Partial epigenetic reprogramming may well belong to this family of breakthroughs.
Modest and, for that, powerful
There is a sentence from Hal Barron, the CEO of Altos Labs, that deserves to be quoted because it radically shifts the debate. Barron is a cardiologist by training, a former executive at GSK and Calico. He says: delaying the onset of Alzheimer's disease by just three years would have an effect on global public health equivalent to curing all cancers today.
Three years, not a hundred and fifty years of life. The reason is mathematical: the prevalence of Alzheimer's follows an exponential curve with age. Shifting that curve by three years is enough to collapse the number of cases and with them the social, medical and human burden of a disease that today affects more than 50 million people worldwide. If epigenetic reprogramming simply manages to slow the ageing of brain cells, even modestly, even partially, the effect on that curve could be precisely of that order.
This way of framing the problem makes this research very different from the transhumanist promises that have sometimes accompanied it. The best researchers in the field do not promise eternity. They promise less Alzheimer's, less cardiovascular disease, fewer age-related cancers. They promise time in good health, and they are demonstrating it cell by cell.
A slow innovation, then sudden
This story is, in many respects, a textbook case of scientific innovation. Not the Hollywood innovation of the isolated genius who changes the world overnight. Real innovation, the kind that looks like slow sedimentation, punctuated by moments of breakthrough that are only visible in hindsight.
Between Yamanaka's publication in 2006 and the first human clinical trial in 2026, twenty years passed. That is long on the scale of a human career but extremely short on the scale of medical biology, where most fundamental discoveries take forty to fifty years to produce their first clinical effects. Penicillin was discovered in 1928 by Fleming and was not produced at industrial scale until 1942. CRISPR was described in principle in 2012 and the first gene therapies based on it only reached the market in 2023, eleven years later.
The pace of rejuvenation biology is accelerating, driven by three converging factors. First, the measurement tools: epigenetic clocks now make it possible to quantify biological age objectively, which turns clinical trials into finally rigorous exercises. Then, the delivery tools: the viral vectors derived from gene therapy have progressed enormously in ten years and with them the ability to deliver reprogramming factors into precise tissues without toxicity. Finally, artificial intelligence applied to molecule discovery, which makes it possible to screen millions of candidates in a few weeks to identify chemical cocktails able to replace the Yamanaka factors with classic drugs, easier to administer.
This triple progress explains why the current pace looks like an acceleration. What took ten years now takes two. What seemed inaccessible in 2015 is the subject of clinical trials in 2026.
What remains to be solved
Not everything is settled, far from it. Partial reprogramming works on isolated cells in the laboratory. It is starting to work on whole organs outside the body. What is not yet understood is how to apply it safely to a complete living organism.
The Yamanaka factors are proto-oncogenes. Applied too long, or in the wrong conditions, they can induce tumours. All the technical difficulty lies in the precise mastery of dosage, duration of application, delivery vector, and this for each tissue, each organ, each indication. It is a problem of formidable complexity. Researchers speak of it openly and advance only with caution.
There is also a measurement challenge. Epigenetic clocks are precious but they measure a correlation with age, not necessarily with biological function. A cell can display an epigenome rejuvenated by thirty years while remaining less capable than a truly young cell. Second-generation biomarkers, which directly measure tissue function, are being developed but do not yet reach the maturity needed for regulation.
And then there are questions that science alone cannot settle. Which patients will be able to access these therapies? At what price? How to integrate, into health systems designed to treat diseases, therapies that modify the pace of ageing itself? What implications for pension schemes, for the economics of care, for equity between countries and between generations? These questions are not yet seriously debated at the level of regulators or payers. The gap between the speed of science and the slowness of institutions is, for now, almost invisible to the general public.
A breakthrough not yet visible
Real scientific breakthroughs are recognised by the fact that they occur in distant laboratories, in publications no one reads outside a narrow circle, during years when the world is looking elsewhere. Then they suddenly appear on the front page and become obvious.
Epigenetic reprogramming is precisely at that stage. The publications pile up, the clinical trials begin, the funding flows in billions. And the general public is still talking about superfoods and intermittent fasting to age well. The gap between the research frontier and common culture has never been so wide.
It is precisely in that gap that the next decade will play out. The countries, the laboratories, the companies that will have understood the nature of the breakthrough will be able to position themselves in markets that do not yet exist, and those that wait for the news to arrive in the mainstream press will arrive ten years late.
Innovation, in all its aspects, always follows this mechanism. It begins with a fact no one sees, continues with an experiment that goes unnoticed, crosses a decade of patient underground work and ends up imposing itself on everyone as a retrospective obviousness. Pasteur lived it, Yamanaka is living it today. And in ten years, perhaps, patients with glaucoma will see again because a Japanese biologist asked, twenty years ago, a question no one had thought to formulate.
To go further
- To read: Lifespan by David Sinclair (HarperCollins, 2019), the accessible but documented manifesto of the Harvard researcher on the epigenetic theory of ageing.
- To read: the article Cell Rejuvenation published in The New York Times Magazine of 27 April 2026 gives a narrative and well-sourced overview of the current state of the research.
- To watch: Juan Carlos Izpisua Belmonte's talk at the All-In Summit 2024 remains, to this day, the clearest and most rigorous account for a general audience of what partial reprogramming is, and is not.
- To follow: the ER-100 clinical trial by Life Biosciences, whose first six-month results are expected in the autumn of 2026, and the next wave of Altos Labs publications on the reprogramming of human organs ex vivo.